DRUG REPURPOSING/REPOSITIONING: APPROACHES AND CHALLENGES

A DISSERTATION

SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF THE DEGREE

OF

MASTERS OF SCIENCE

IN

BIOTECHNOLOGY

Submitted by:

Ayushi Singh

2K19/MSCBIO/26

Under the supervision of

DR. YASHA HASIJA

DEPARTMENT OF BIOTECHNOLOGY

DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi College of Engineering)

Bawana Road, Delhi-110042

28th MAY, 2021

DELHI TECHNOLOGICAL UNIVERSITY

(Formerly Delhi College of Engineering)

Bawana Road, Delhi-110042

DECLARATION

I hereby certify that the work which is presented in the research work entitled "Drug repurposing/repositioning: Approaches and Challenges" in fulfillment of the requirement for the award of Degree of Masters in Science in Biotechnology and submitted to the Department of Biotechnology, Delhi Technological University, Delhi is an authentic record of my own work, carried during a period from 7th Jan 20121 to 28th May 2021, under the supervision of Dr. Yasha Hasija.

The matter presented in this thesis has not been submitted by me for the award of any other degree of this or any other university. This work has been communicated in SCI indexed journal with the following details:

Title of Paper: Drug Repurposing/Repositioning: Approaches and Challenges

Author's name: Dr. Yasha Hasija, Ayushi Singh

Name of Journal: Turkish Journal of Pharmaceutical Sciences

Status of Paper: Communicated

Dated of paper communication: 28th May 2021

Date of paper acceptance: Waiting

Date of paper publication: Waiting

DEPARTMENT OF BIOTECHNOLOGY

DELHI TECHNLOGICAL UNIVERSITY

(Formerly Delhi College of Engineering)

Bawana Road, Delhi-110042

CERTIFICATE

I hereby certify that the Project Dissertation titled "Drug Repurposing/Repositioning: Approaches and Challenges" which is submitted by Ayushi Singh, 2K19/MSCBIO/26, Department of Biotechnology, Delhi Technological University, Delhi in partial fulfillment of the requirement for the award of the degree of Master of Technology, is a record of the project work carried out by the student under my supervision. To the best of my knowledge this work has not been submitted in part or full for any Degree or Diploma to this University or elsewhere.

Place: Delhi

Delhi: 1st June, 2021



DR. YASHA HASIJA

SUPERVISOR

ASSOCIATE PROFESSOR

DEPARTMENT OF BIOTECHNOLOGY, DTU

ACKNOWLEDGEMENT

The attainment and outcome of this project were possible by the counselling and assistance from many people. I am fortunate to have received this all along with the accomplishment of my project. Firstly, I'd like to convey my thanks to my supervisor and mentor Dr. Yasha Hasija for her constant help and guidance for my study on Drug Repurposing and repositioning, for her immense knowledge, motivation, enthusiasm and patience. Her guidance guided me a lot with the research and writing of my dissertation.

I would also like to extend my hearty thanks to our Head of the Department, Prof. Pravir Kumar, who were always attentive towards our problems and mistakes and always helped us throughout our year of study with him. He guided us as a teacher as a mentor and a friend which I am immensely grateful for.

I would like to extend my gratitude towards my parents for their encouragement which helped me in the completion of this project.

My thanks and appreciation goes to all my college mates in helping the project and colleagues who have readily supported me to the best of their capabilities.

Considering the situation, we're all in since the pandemic I would like to thank my parents who supported me, helped me, counselled me, nourished me without any complaints. They made me stay optimistic even during the worst of times.

At last, I would like to thank the staff of our department of Biotechnology, Delhi Technological University without whom my work could not have been completed, they helped me from the first day itself to access various commodities and information. Provided us with proper materials during our practical lab

classes. Also, the computer staff of the college also supported and helped us online and offline mode and made it easier for us to study.

Finally, I would like to thank any person who has helped me directly or indirectly throughout my master's degree and my dissertation.



AYUSHI SINGH

ABSTRACT

This paper highlights the approaches, opportunities and challenges faced by the fairly new techniques of drug repurposing. The development of new drugs from older, rejected or already existing drugs by a cost effective and a time-efficient process involving various assays is discussed below. The paper aims to draw attention towards dissimilarities between traditional drug development and newer processes of drug repositioning & experimental and computational approaches. This project deals with the techniques involved, the shortcomings and the numerous drugs repurposed with the help of various assay and methodologies with examples. It also discusses the types of drugs that can be repurposed and the pros and cons. Drug repositioning may turn into a vital methodology for drug disclosure as far as time-and capital-competency contrasting with ordinary medication revelation and advancement measure. Drugs can be re-purposed by various ways which include experimental and the *in-silico* based approach. Most approaches employed are according to the first stage of identification of lead candidate since it needs more sophisticated and systematic approaches. There are various other methodologies that are employed in the drug repurposing/repositioning like phenotype screenings, targeting 3-D structures among others. Drug repurposing offers a great scope for many orphan diseases as well but great opportunities come with challenges.

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

LIST OF SYMBOLS, ABBREVIATIONS AND NOMENCLATURES

FDA	Food and Drug Administration
DR	Drug Repositioning
R&D	Research and Development
DB	Databases
RNA	Ribonucleic Acid
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
MERS	Middle East Respiratory Syndrome
PDE inhibitor	Phosphodiesterase Inhibitor
COVID	Corona Virus Disease
UTI	Urinary Tract Infection
NSAID	Nonsteroidal anti-inflammatory drugs
CVDs	Cardiovascular Diseases
MS	Multiple sclerosis
SSNRI	Selective serotonin reuptake inhibitors

1. INTRODUCTION

Drug repositioning, also known as drug remodeling, repurposing, rescuing, recycling can be defined as a process of recognizing new therapeutic purposes/uses for already marketed drugs. Drug repositioning has become quite popular in the recent years considering how the process of drug discovery can be reduced to minimal steps. Drug development is a high-risk process with comparatively large investment and time consumption. Drug repurposing as compared to processes of drug discovery include lesser risks, is economical and efficient.

Drug discovery on an average takes up to 15-20 years and $10-$12 billion approximately, and the triumph rate for evolving a new molecular component is approximately 2.02%. Investment on drug development is increasing steadily but since 1995, a decline in the quantity of drugs sanctioned by Food and Drug Administration has been noted. Hence, this new approach is a trending way now used to discover drugs in a cost-effective manner with relatively low investment.

Drug repurposing was a coincidental accomplishment back in mid 1920s. With decades of developments in techniques and approaches further processes have made easier for existing drugs/failed drugs/experimental/old FDA approved drugs to be redirected into new uses.

A large portion of the successful and most popular medication repurposing stories (for example sildenafil, valproic acid, aspirin, minoxidil) have arisen, if not from unanticipated perceptions, from haphazard ('field') determination measures, frequently depending on the definitely known toxicology of a medication, to tackle a clinical issue from another area. As of late, however, the medication disclosure local area has focused on the execution of coordinated, precise, information driven medication repurposing approaches, which much of the time incorporate

computational help. There, one may specify signs coordinating of proteomic or transcriptomic information; sub-atomic affinity estimations; structure-based virtual tests &; efficient investigation of electronic wellbeing clinical preliminary and records and post-promoting observation information.



Fig 1. Phases in drug development in comparison to phases in drug repurposing

Drug development involves a series of steps: discovery of lead compound and pre-clinical stage, clinical development, regulatory approval, safety review, marketing. Whereas drug repurposing involves fewer steps like clinical approval of the drug, selection and validation, clinical development, post -marketing surveillance (as depicted in Fig 1).

Sildenafil (Viagra), was introduced in the market as an anti-anginal drug and as the medication for coronary artery disease, is considered to be a benchmark in drug repurposing, since at present it is being widely used as a drug for erectile dysfunction. Thalidomide, was developed as a medication of immunomodulation in expecting women but was taken off the markets since

it gave their infants serious birth defects. This drug was allowed to enter the markets again by FDA after a series of researches and released in the markets as a medication for multiple myeloma. In 1960s, Amantadine was released in the markets for the treatment of influenza infections. A patient suffering from Parkinson's came forward claiming that her symptoms had improved after its use. Amantadine was found to be functional in the medication of neurological disorders & was approved by FDA for the same. (Ref 1)

Such examples created a history and paved the way for drug repurposing and a prominent future. Although this process isn't new, it picked up momentum in the last 2 decades and now generates around 25% of the annual pharmaceutical revenue.

Fig 2. Processes of drug discovery and development: 10-20 years

Fig 3. Drug repurposing: 3-12 years

DRUG, CATEGORY	ORIGINAL INDICATIONS	NEW PURPOSE/ INDICATION
Sildenafil, PDE inhibitor	Pulmonary arterial hypertension, Angina Pectoris	Erectile dysfunction
Thalidomide, Immune modulator	Morning sickness, Immuno-modulation	Multiple myeloma, Leprosy
Valproic acid, Anti-epileptic	Epilepsy	Migraine headache, Manic depression, Bipolar disorders
Retinoic acid	Acne	Acute leukemia
Remdesivir, Anti-viral	Influenza, Ebola (failed in clinical trial)	COVID-19
Propranolol, Beta-blocker	Hypertension	Migraine
Nitroxoline, Anti-viral	UTI	Breast, bladder and pancreatic cancer
Colchicine, Anti-inflammatory agent	Gout, Gouty arthritis	Pericarditis, COVID (under development)
Aspirin, NSAID	Pain and inflammatory	CVDs (anti-platelet), Prostate cancer (under development)
Avermectin, Anthelmintic	River blindness, Elephantiasis	Tuberculosis
Dimethyl fumarate, anti-allergic	Psoriasis	Multiple sclerosis (MS)
Disulfiram, Acetaldehyde dehydrogenase inhibitor	Chronic alcoholism	Cancer
Minoxidil, Antiprogestin	Hypertension	Androgenic alopecia
Penfluridol/ Pimozide, Anti-psychotics	Psychiatric illness	Breast cancer
Everolimus, Immune suppressant	Immune suppressant	Pancreatic neuroendocrine tumors
Duloxetine, SSNRI	Depression	Generalized anxiety disorders, fibromyalgia, chronic musculoskeletal pain, neuropathic pain
Isoniazid, Anti-tubercular	Tuberculosis	Certain types of tumor

Fig 4. Few examples of drugs that were repurposed from already approved drugs

1.1 WHICH DRUGS CAN BE REPURPOSED?

Drug repurposing involves finding alternative uses for an already existing drug with definite composition. It mostly involves developing failed drugs or approved drugs that weren't quite successful, to expand the area of treatment for neglected or rare diseases. Drugs usually employed for repurposing techniques are failed, rejected, investigational, already marketed or pro-drugs including drugs that are discontinued or abandoned. Already existing drugs are employed because of known components, their dosage and side effects. Already known

components are the reason for reduced clinical trial steps, reducing the time and cost for reaching the markets. Known components are favored since the known possibilities of combining with other drugs would allow a better and more effective treatment. Most of them also have demonstrated safety in humans which reduces Phase 1 of clinical trial. [6]

A large portion of the successful and most popular medication repurposing stories (for example sildenafil, valproic acid, aspirin, minoxidil) have arisen, if not from unanticipated perceptions, from haphazard ('field') determination measures, frequently depending on the definitely known toxicology of a medication, to tackle a clinical issue from another area. As of late, however, the medication disclosure local area has focused on the execution of coordinated, precise, information driven medication repurposing approaches, which much of the time incorporate computational help. There, one may specify signs coordinating of proteomic or transcriptomic information; sub-atomic affinity estimations; structure-based virtual tests &; efficient investigation of electronic wellbeing clinical preliminary and records and post-promoting observation information.

Existing chains of pharmaceutical supplies facilitate new formulations and distributions of drugs manufactured. New mechanisms of action for older drugs might be discovered by repositioning. Recent developments in the field of network biology and genomics have led to better research towards repurposing and drug repositioning which were earlier thought to be discovered ‘by chance’. Better technology in the fields of medicine has now made it possible to identify the gene involved responsible for a specific disease and whether the drug is able to target the gene responsible.

	DRUG DISCOVERY	DRUG REPURPOSING
YEARS (IN MAKING)	15-20 YEARS	9-10 YEARS
COST ($)	$12 BILLION	$1.6 BILLION
RISK RATE	HIGH	LOW
PHASES IN MAKING	6 PHASES (INCLUDING POST-MARKETING SURVEILLANCE)	4 PHASES (INCLUDING POST-MARKETING SURVEILLANCE)
CHANCES OF BEING APPROVED	2.01% (LOW)	33% (COMPARATIVELY HIGH)
EFFICIENCY	LOW	HIGH

Table 1. Depicting different parameters for comparison

1.2 POSSIBLE METHODS EMPLOYED FOR DRUG REPOSITIONING:

Drug repurposing involves 3 main steps that include,

(i) Identifying a candidate (target) and generating a new hypothesis for the same.

(ii) Search for a signaling pathway for the drug/disease.

(iii) Testing the effectiveness of the drugs in 2^{nd} & 3^{rd} phase of clinical prelims,

locating target candidate being the most crucial step. [6]

Drugs can be re-purposed by various ways which include experimental and the *in-silico* based approach. Most approaches employed are according to the first stage of identification of lead candidate since it needs more sophisticated and systematic approaches.

1.2.1 Experimental approach:

- Identification of target candidate- To find all possible drug binding targets various techniques are used like mass spectrometry and chromatography. Various tests involving mass spectrometry led to the discovery that a drug can combine with almost 20 contrasting protein kinases which can be medicated with appropriate drugs.
- It is also referred to as activity-based repurposing referring to the screening and testing of initially taken drugs for new pharmacological symptoms based on results of experimental evaluations.
- These involve screening of cell-based and protein target-based screens without needing any structural data of the target protein in *in-vitro* or *in-vivo* models of disease.
- Requirement of repositioned drugs is expanded to remunerate the low achievement pace of regular or traditional drug revelation measures. Then again, the accessibility of set up drug libraries drove specialists to make more objective plans contrasted with information-based medication repositioning. The expression "movement-based medication repositioning" represents testing real medications in examines.

1.2.2 *In-silico* method:

- It is classified as either disease or drug-centric, wherein disease-centric, new drugs for the existing diseases are tried and in drug-centric new signs for existing medications are detected.
- Also referred to as computational approach as it involves using bioinformatics tools and computational biology for virtual screening of chemical databases libraries and public databases of huge drug.
- In this approach, molecular interactivity amongst various drug molecules and proteins targets are monitored to achieve, identify potential bioactive molecules.

- *In-silico* method has gathered quite an approval in the past few decades because of remarkable accomplishment in drug discovery strategies.
- It has more advantages than experimental approaches, including reduced time, lower chances of failure and reduced cost of development and research.



Fig 5. *in silico* approach workflow (Ref 12)

- Information and knowledge-based drug repurposing is exclusively reliant with respect to explores' information and capacity to decipher the logical perceptions or just happenstances. It isn't just a period and cost-productive interaction, yet additionally simple to approve in pre-clinical and clinical examinations if perceptions were tentatively researched. Then again, it isn't the orderly route contrasting with the other DR strategies, and along these lines it might seem dangerous. *In-silico* frameworks has decreased duration & capital, notwithstanding, generally relies on the accessibility of the exploratory information, for example, construction or quality articulation profiles

from the start. The organic meaning of the accepted destination anticipated by the computationally strategy should likewise be tentatively evaluated. Then again, action-based drug repurposing is time & work devouring; needing a whole assortment of existing medications, specific gear and foster a screening measure, yet it tends to be utilized without requiring primary data of target proteins or data set. In addition, movement-based drug repurposing is not difficult to approve since it encounters less bogus productive rates concerning *in-silico* repurposing.

Experimental approach	***In-silico* based method**
Also known as activity-based screening (*in vivo* and *in vitro)*	Also known as virtual screening (computational)
Involves cell-based and screening target-site assays	Involves protein target-based screening
Doesn't need any medication-prompted cell and infection phenotypic information or underlying information of targeted proteins	Requires phenotypic and structural data for screening
Duration & labor consuming	Duration & labor productive
Rates of incorrect positives during processing are low	Rates of incorrect positives during processing are high
High risks of failure	Low risks of failure

Table 2. Major dissimilarities between experimental and *in-silico* procedures

There are various other methodologies that are employed in the drug repurposing/repositioning like phenotype screenings, targeting 3-D structures among others (Ref 2). Target-based

methods and drug-based phenotype and screening methods report for almost 50% of drugs and molecules approved by FDA (as depicted in Table 3).

METHODOLOGY	**APPROACH**	**EXAMPLE(S)**
Phenotypic screening	*In-vitro and in-vivo* testing	Rituximab (breast cancer), Viagra (erectile dysfunction)
Target 3D structure, information on narcotics and ligands	Ligand based screening, molecular docking, *in silico* screening	Etoposide (bladder cancer), Fluorouracil (lung cancer)
Information from databases on clinical trials	Drug similarity researches	No drug approved by FDA yet.
Information on available pathway information from databases	Detection of disease mode of action, Addressing of key targets	Vismodegib (skin cancer)
Drug omics data	Researches on gene signatures	Fasudil (neurodegenerative diseases)

Disease omics/ genetic info available	Identifying key targets by genomics/ Studying gene signatures	No medication approved by FDA yet.
Drug omics data/ disease omics	Drugs and disease similarities	Topiramate (inflammatory bowel disease), Cimetidine (lung cancer).

Table 3. Other methodologies along with suitable examples [1]

1.2.3 PHENOTYPIC SCREENING METHODS: These methods are used due to their flexibility to detect and analyze the molecular entities and diseases. These biological tests involve identification of specific drugs and disease models.

1.2.4 TARGET 3D STRUCTURES: These employ methods like *in-silico* approaches for molecular docking and ligand-based testing and *in-vivo* and *in-vitro* testing for biomarkers and drug components for a specific target. These have better chances than blind-search testing in discovering of drug leads. These methods are also time efficient and less risk prone.

1.2.5 INFORMATION FROM DATABASES ON CLINICAL TRIALS: These methods involve screening of data from various DB that furnish data on medications & their respective structures, effects, side-effects, pathways, profiles, targeting processes. The collected data is

utilized in predicting new pathways and mechanisms for drug functioning. The expression "knowledge/information-based medication repurposing" addresses drug repositioning dependent on information on the clinical specialists or analysts and their capacity to decipher logical perceptions or just incidents. The principal instances of medication repositioning were found fortunately while dealing with another sickness. Later, comparative infection indications, sharing adjusted pathways or the need of mix treatments, driven specialists to search for perceptions and repurpose drugs for a sickness as opposed to the initially focused on one. Thus, these examples of overcoming adversity have become unmistakable and as yet rehearsing with regards to sedate repositioning.

1.2.6 DISEASE OMICS: These methods are pathway based, they use data to establish specific pathways to a disease and the key targets for re-invented drugs. These methods involve usage of available metabolic pathways for shrinking/reducing large amounts of proteins and it's signaling network to fewer and specific network proteins.

METHODOLOGY
DRUG ↓
TARGET ↓
PATHWAY ↓
DISEASE ↓

SIDE EFFECTS

Table 4. The basic methodology in drug repositioning

Existing chains of pharmaceutical supplies facilitate new formulations and distributions of drugs manufactured. New mechanisms of action for older drugs might be discovered by repositioning. Recent developments in the field of network biology and genomics have led to better research towards repurposing and drug repositioning which were earlier thought to be discovered 'by chance'. Better technology in the fields of medicine has now made it possible to identify the gene involved responsible for a specific disease and whether the drug is able to target the gene responsible.

STRATEGY TIERS	REPOSITIONED DRUGS
S1: Strategy 1: Serendipitous observation	Buproprion Thalidomide
S2: Strategy 2: Observation of novel activity (rational approach)	Nelfinavir
S3: Strategy 3: New drug-target interaction	Imatinib Sunitinib
S4: Strategy 4: New roles for existing protein-target	Crizotinib Everolimus
S5: Strategy 5: New biochemical pathways	Duloxetine
S6: Strategy 6: Disease-specific repositioning	Aspirin Metformin
S7: Strategy 7: Unexpected side effects	Sildenafil Minoxidil

Fig 6. Strategy tiers for drug repurposing with repositioned drug examples. (Ref 1)

1.3 IS DRUG REPURPOSING WORTHWHILE THE ATTEMPT?

Not a lot is expected from repurposing screens to recognize in excess a few of useful medications for a specific sign. In any case, even during the Covid pandemic, repurposed endeavors should have been conveyed when we have the rise of another infection, since, supposing that there is something that is promptly addressable to the populace, you totally need to distinguish it quickly and take it forward."

For example, specialists and researchers tried Remdesivir on the grounds that it was intended to close down RNA-subordinate RNA polymerases, an enzyme found in numerous viruses, including SARS-CoV-2. Remdesivir was initially evolved to treat hepatitis C and later went through a clinical preliminary during the 2016 Ebola episode, where it neglected to show any adequacy. Animal screenings had shown it could treat Covid, the one that leads to MERS (Middle East respiratory disorder). Hence, during Covid, it was the conspicuous thing to test," since it had its clinical information from its preliminary screenings with Ebola."

1.4 CHALLENGES: Despite promising results and opportunities repurposing is faced by various challenges. Drug repurposing is for the most part stressed inside benefits, numerous difficulties merit consideration. Not all endorsed non-malignant growth medications ought to be tried for disease treatment without substantial sub-atomic bits of knowledge into their powerful potency. There are additionally a few examinations that consider deserted medications for repurposing, in any case, additional consideration in choosing deserted medications is suggested in regards to deficient pharmacokinetic and pharmacodynamic information. Other point will be vulnerabilities, if the medication dosages, plans, & courses of

organization for the first sign are like the need of the counter malignant growth sign. Albeit supported medication procured by means of drug repurposing strategies don't function true to form, constructions and focuses of the endorsed medications can likewise facilitate in planning enhanced medication with new characteristics, for example, greater water solvency, expanded particularity, longer maintenance duration, and so forth.

- Lack of financial support: Since the new evidence is based on past information, for example, pharmacokinetic and producing information, the medication advancement course of events is significantly abbreviated, just like the necessary venture. The fundamental benefit of repositioned competitors is that it numerous times they have effectively demonstrated to be adequately protected in pre-symptomatic models & in any event, near beginning phase preliminaries in people, hence being more averse to fall flat from a security perspective in ensuing viability preliminaries (except if drug–illness associations are found). On account of supported medications, they have effectively excelled objective preliminaries & administrative examination, & have effectively gone through post-promoting observation.

- Lower drug prices

- Short patent durations: There are a few lawful viewpoints that could debilitate licensing another clinical use or potentially the implementation of patent rights, subsequently reducing the motivations for drug repurposing. In the first place, some public enactments hinder getting a patent for 2nd or further clinical uses (in spite of the fact that, it is feasible to ensure a repositioned clinical use in a large portion of the significant drug markets). Also, numerous potential repositioning utilizes have effectively

accounted for in the specific writing or are as of now being abused in the patient-contact experience as off-mark, un-enrolled utilizes. Regardless of whether such functions have yet not been embraced by administered clinical preliminaries, the data is now in the public space & influences curiosity & thus, legal-controllability.

- The way toward evolving new functions out of the extent from the first clinical sign for remaining medications is known as medication repositioning. Repositioning existing medications for new signs can offer a superior danger versus-reward compromise as contrasted and other medication advancement techniques, and can assist with conveying the efficiency builds the business needs while moving the locus of creation to biotechnology organizations.

- Low returns on investments

- Most pharmaceutical industries shy away from investing in such clinical trials: In spite of a racked medication could be viewed as an inactive funds or a botched or delayed moments, some drug organizations are less disposed than rest to deliver their synthetic databases (for example failed drugs) to branch the potential uses of their compound assortments (or c/would demonstrate extremely particular at picking accomplices), which could represent the principal boundary to sedate repositioning possibilities if a potential repositioned sign befalls out of the association's centre sickness region. [17]

- Techniques involves factors such as technology, commercial models, patents among others deeming it a complex process: Each computational methodology accompanies its own benefits and cut-off points dependent on the issue to be tackled and on the sort, quality, and amount of data accessible about the issue in the writing or out in the

public/private information bases. For instance, atomic docking requires high goal-specific data of medications and targets

- Requires massive amounts of medical data. [7]: While the open-source model is dynamically making strides inside the medication revelation local area [11], free to particular kinds of (significant) information (for example clinical preliminaries) is as yet restricted. Regardless of whether openness was not an issue, a few sorts of information are less well disposed to information mining, coordination and control (for example imaging information) or are in some cases offered in a non-normalized way [8]. Coordinating various sorts of information has additionally demonstrated computationally requesting as it expands the force of investigation

- Difficulties in applying the theories into processes.

- Inaccurate, biased or missing data leads to false or varied results: populace and varieties dependent on topographic district could be a different test for narcotics repurposing. Nonetheless, especially computational DR systems dependent on signature coordinating with procedures may give articulation marks for every person and expectedly convert into a customized drug repurposing.

- The need for fresh metrics for accuracies like sensitivity, recall, drug targets for better comparisons and evaluations.

- The possibility of repositioning space being used up [17]: In spite of the universe of disorders requiring improved helpful arrangements (or, restorative arrangements) is

without a doubt enormous, it very well might be contended that precise medication repurposing efforts may quickly deplete the medication repurposing possibilities for a given infection (all things considered, the quantity of repurposing applicants is restricted and it extends rather gradually quite a long time after year).

- For instance, a few high-throughput screens coordinated to the recognizable proof of trypanocide-al repositioned narcotics with potential implementations as medicines for Chagas sickness are being accounted for consistently [13,16,17,21], and this without mulling over past low-through-put tests [16,19] & wet screens or *in-silico* screens zeroed in on explicit medication targets & containing trial approval of the actions (example, refs [13,25]). A substantial inquiry that arises is the number of much repositioned-arranged phenotypic results zeroed in on *Trypanosoma cruzi* w/could be legitimized. Similarly, we c/would inquire as to whether eagerness in drug repurposing would rot progressively as progressive deliberate screens on assortments of realized medications are executed.

In my opinion, target-based screens may hold extra worth. When an endorsed medicine has demonstrated its movement on an unexpected site, the entire arrangement of mixtures from a drug-organisations that have a similar dynamic framework could be investigated (regularly, many such mixtures are produced & employed to assemble structural–action connections through hit-to-lead & lead-streamlining processes; the lead compound for a restorative objective may not really be something similar for a different state).

2. CONCLUSION

Despite drug development being a flagbearer for a lot of drugs discovering techniques is still quite risk-prone, time consuming, and expensive. Hence, techniques like ‘drug repositioning’ have come into limelight due to their faster and cheaper ways gaining attention from pharma companies for launching advanced narcotics in the markets. Drug repurposing techniques have proven to be more systematic and sophisticated in the recognition of drug components with unknown therapeutic evidences. As repurposing offers higher chances of achievement, less research period and comparatively less capital risk, it has achieved an increase in demand. Drug repurposing offers a great scope for many orphan diseases as well but great opportunities come with challenges.

Once and once more, drug repositioning is being supported as intriguing technique to investigate latest drug answers for uncommon & rare illnesses (a considerable lot of the accessible meds for such positions can be viewed as repositioned drug). The seek after of drug answers for rare and orphan illnesses, while perhaps not especially productive in absolutely monetary terms, infers different types of significant worth, like corporate social duty and the ensuing expanded social mindfulness/impression of drug organizations. Social duty includes supporting the balance between monetary turn of events and the government assistance of the general public and climate; one of its objectives is, in this way, assisting with reduce or eliminate hindrances like monetary condition. Government associations, on their part, additionally have the way to advance such drives however extraordinary practical motivations: it is, at that point, crucial for acquire and produce mindfulness that monetary misfortune because of uncommon and ignored conditions significantly surpasses the necessary speculation to foster new helpful arrangements.

In spite of the fact that drug repurposing should essentially reduce the duration and capital, keeping in mind the hurdles related with stage 2nd and 3rd medical preliminaries, disappointment in the mentioned stages can't be decreased by narcotics repurposing. Much capital, bigger quantity of patients and extensive hours are required after stage 2 of clinical preliminary with existing disappointment possibility, sadly. IPR and administrative guidelines involving the conversations over off-patent medications & respective mode of measures licenses are different issues considered for the marketing of advanced malignancy sign of a generally endorsed medication as noted above.

3. REFERENCES:

1. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. By Mithun Rudrapal, Shubham J. Khairnar and Anil G. Jadhav pp: July 13th 2020 DOI:10.5772/intechopen.93193

2. Drug repurposing: progress, challenges and recommendations**.** Sudeep Pushpakom, Francesco, Iorio, Patrick A. Eyers, K. Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, Tim Guilliams, Joanna Latimer, Christine McNamee, Alan Norris, Philippe Sanseau, David Cavalla & Munir Pirmohamed, pp: 12 October 2018, *Nature Reviews Drug Discovery* volume 18, pages41–58(2019)

3. Drug Repurposing and Repositioning Workshop Summary (2014) **Chapter:** 6 Increasing the Efficiency and Success of Repurposing, page:49

4. Drug Repurposing and Orphan Disease Therapeutics, By Neha Dhir, Ashish Jain, Dhruv Mahendru, Ajay Prakash and Bikash Medhi, pp: April 23rd 2020. DOI:10.5772/intechopen.91941.

5. Drug repurposing: Advantages and Key Approaches, By Harsha Agarwal, Sagacious IP, pp: Jan 04, 2021.

6. Drug repositioning: New approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. By Zheng Yao Low, Isra Ahmad Farouk, Sunil Kumar Lal, 12(9) pp: September 2020. Doi: 10.3390/v12091058

7. Drug repurposing: progress, challenges and recommendations. By Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers, K. Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, Tim Guilliams, Joanna Latimer, Christine McNamee, Alan Norris, Philippe Sanseau, David Cavalla and Munir Pirmohamed. Nature Reviews Drug Discovery. Vol 18, Page 41-58 (2019)

8. Drug Repositioning: Increasing opportunities of drug repurposing for treating breast cancer by the integration of molecular, histological and systematic approaches. By Harras J. Khan, Sagar O. Rohondia, Zainab Sabry Othman Ahmed, Nirav Zalavadiya, Q. Ping Dou. Chapter: 5. Pages 121-172. Pp: 4 September, 2020.

9. Is drug repurposing worth the effort? By Bethany Halford, January 25, 2021. A version of this story appeared in Volume 99, Issue 3. https://cen.acs.org/pharmaceuticals/drug-discovery/Is-drug-repurposing-worth-the-effort/99/i3

10. Pantziarka Pan, Verbaanderd Ciska, Sukhatme Vidula, Capistrano Rica, Crispino Sergio, Gyawali Bishal, Rooman Ilse, Van Nuffel An MT, Meheus Lydie, Sukhatme Vikas P and Bouche Gauthier (2018) ReDO_DB: **the repurposing drugs in oncology database** *ecancer 12 886,* https://www.anticancerfund.org/en/redo-db#:~:text=ReDO_DB%20is%20a%20curated%20listing,observational%20studies%20and%20clinical%20trials.

11. Fetro C, Scherman D. Drug repurposing in rare diseases: Myths and reality. Therapie. 2020 Apr;75(2):157-160. doi: 10.1016/j.therap.2020.02.006. Epub 2020 Feb 13. PMID: 32241561.

12. Jarada, T.N., Rokne, J.G. & Alhajj, R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. *J Cheminform* **12,** 46 (2020). https://doi.org/10.1186/s13321-020-00450-7

13. Carolina L. Bellera, Manuel Llanos, Melisa E. Gantner, Santiago Rodriguez, Luciana Gavernet, Marcelo Comini, Alan Talevi. (2020) Can drug repurposing strategies be the solution to the COVID-19 crisis?. *Expert Opinion on Drug Discovery* 0:0, pages 1-8.

14. Navneet Kumar, Anuj Gahlawat, Rajaram Naresh Kumar, Yash Pal Singh, Gyan Modi, Prabha Garg. (2020) Drug repurposing for Alzheimer's disease: *in silico* and *in vitro* investigation of FDA-approved drugs as acetylcholinesterase inhibitors. *Journal of Biomolecular Structure and Dynamics* 0:0, pages 1-15

15. Shubhangi Kandwal, Darren Fayne. (2020) Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of action. *Journal of Biomolecular Structure and Dynamics* 0:0, pages 1-15.

16. Zsuzsanna Ida Petykó, András Inotai, Anke-Peggy Holtorf, Diana Brixner, Zoltán Kaló. (2020) Barriers and facilitators of exploiting the potential of value-added

medicines. *Expert Review of Pharmacoeconomics & Outcomes Research* 20:3, pages 229-236.

17. Alan Talevi & Carolina L. Bellera (2020) Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics, Expert Opinion on Drug Discovery, 15:4, 397-401, DOI: 10.1080/17460441.2020.1704729

18. Naylor S, Kauppi DM, Schonfeld JP. Therapeutic drug repurposing, repositioning and rescue part II: business review. Drug Discovery World. 2015;16(2):57–72.

19. Allison M. NCATS launches drug repurposing program. Nat Biotechnol. 2012;30(7):571–572.

20. Naylor S, Kauppi DM, Schonfeld JP. Therapeutic drug repurposing, repositioning and rescue: part III: market exclusivity using intellectual property and regulatory pathways. Drug Discovery World. 2015;16(3):62–69.

21. Oprea TI, Overington JP. Computational and practical aspects of drug repositioning. Assay Drug Dev Technol. 2015;13(6):299–306.

22. S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, et al., Drug repurposing: progress, challenges and recommendations, Nature reviews drug discovery **18** (1) (2019) 41–58.

23. T. T. Ashburn, K. B. Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nature reviews drug discovery **3** (8) (2004) 673–683.

24. Y. Wang, S. Zhang, F. Li, Y. Zhou, Y. Zhang, Z. Wang, R. Zhang, J. Zhu, Y. Ren, Y. Tan, et al., Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics, Nucleic acids research **48** (D1) (2020) D1031–D1041.

25. J. Berman, Miltefosine, an FDA-approved drug for the 'orphan disease', leishmaniasis, Expert opinion on orphan drugs **3** (6) (2015) 727–735.

26. Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, Eubanks LM, Lustigman S, Kaufmann GF, Janda KD (2010) Repositioning of an existing drug for the neglected tropical disease onchocerciasis. Proc Natl Acad Sci 107(8):3424–3429

27. Love et al. "A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis." *PLOS Neglected Tropical Diseases* 11: e0005373 (2017)

28. Kim T.W. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. *Neurotherapeutics.* 2015; 12: 132-142

29. Bhattarai, D., Singh, S., Jang, Y., Han, S. H., Lee, K., and Choi, Y. (2016). An insight into drug repositioning for the development of novel anti-cancer drugs. *Curr. Top. Med. Chem.* 16, 2156–2168. doi: 10.2174/1568026616666160216153618

30. Chong, C., and Sullivan, D. J. (2007). New uses for old drugs. *Nature* 448, 645–646. doi: 10.1038/448645a

31. Deotarse, P. P., Jain, A. S., Baile, M. B., Kolhe, N. S., and Kulkarni, A. A. (2015). Drug repositioning: a review. *Int. J. Pharma Res. Rev.* 4, 51–58.

32. Gayvert, K. M., Dardenne, E., Cheung, C., Boland, M. R., Lorberbaum, T., Wanjala, J., et al. (2016). A computational drug repositioning approach for targeting oncogenic transcription factors. *Cell Rep.* 15, 2348–2356. doi: 10.1016/j.celrep.2016.05.037

33. Giridhar, R. (2012). Drug discovery: past and present. *J. Adv. Pharm. Technol. Res.* 3:2.

34. Swamidass SJ (2011) Mining small-molecule screens to repurpose drugs. Brief Bioinf 12(4):327–335

35. Alan Talevi (2018) Drug repositioning: current approaches and their implications in the precision medicine era, Expert Review of Precision Medicine and Drug Development, 3:1, 49-61, DOI: 10.1080/23808993.2018.1424535

36. Pan Pantziarka & Lydie Meheus (2018) Omics-driven drug repurposing as a source of innovative therapies in rare cancers, Expert Opinion on Orphan Drugs, 6:9, 513-517, DOI: 10.1080/21678707.2018.1500690

37. Hernandez JJ, Pryszlak M, Smith L, et al. Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics. *Front Oncol*. 2017;7:273. Published 2017 Nov 14. doi:10.3389/fonc.2017.00273

38. Bayoumy, A.B., de Boer, N.K.H., Ansari, A.R. *et al.* Unrealized potential of drug repositioning in Europe during COVID-19 and beyond: a physician's perspective. *J of Pharm Policy and Pract* **13,** 45 (2020). https://doi.org/10.1186/s40545-020-00249-9

39. Trivedi, J.; Mohan, M.; Byrareddy, S.N. Drug Repurposing Approaches to Combating Viral Infections. *J. Clin. Med.* **2020**, *9*, 3777. https://doi.org/10.3390/jcm9113777

40. Goldstein, I.; Lue, T.F.; Padma-Nathan, H.; Rosen, R.C.; Steers, W.D.; Wicker, P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *N Engl. J. Med.* **1998**, *338*, 1397–1404.

41. Emery, P.; Fleischmann, R.; Filipowicz-Sosnowska, A.; Schechtman, J.; Szczepanski, L.; Kavanaugh, A.; Racewicz, A.J.; van Vollenhoven, R.F.; Li, N.F.; Agarwal, S.; et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum.* **2006**, *54*, 1390–1400.